Market Overview

Glytec Receives Two More Patent Allowances for its Insulin Optimization System

Share:

The newest USPTO allowances describe an integrated, connected care
model for optimizing insulin therapy in the outpatient setting.

The United States Patent and Trademark Office has awarded Glytec
two more patent allowances acknowledging the unique characteristics of
its disruptive innovations. The allowances, which comprise a total of 52
claims, describe interactions between Glytec's solution
for insulin titration and multiple current and future-state connected
diabetes technologies and health information systems, including devices,
apps and other form factors for blood glucose measurement, insulin
delivery and patient communication.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180829005199/en/

The USPTO has awarded Glytec two more patent allowances for its insulin optimization system. (Photo: ...

The USPTO has awarded Glytec two more patent allowances for its insulin optimization system. (Photo: Business Wire)

The two new patent allowances depict: [highly abridged and
consolidated]

  • A dosing controller comprising data processing hardware in
    communication with memory hardware, the dosing controller configured
    to: (1) receive sequential scheduled blood glucose time intervals for
    a patient from any of: a healthcare provider computing device, a
    remote computing device during a batch download, a glucose meter upon
    the measuring of blood glucose, a meter manufacturer's computing
    device during a batch download, or a patient device; (2) obtain data
    from a glucose meter for the patient, including blood glucose
    measurements, time periods of such measurements and
    carbohydrate-to-insulin ratios; (3) determine a next recommended
    carbohydrate-to-insulin ratio for each scheduled blood glucose time
    interval based on the representative aggregate blood glucose
    measurement associated with the scheduled blood glucose time interval
    that occurs immediately after the selected time interval; (4) obtain a
    number of carbohydrates consumed by the patient during the selected
    time interval; (5) determine a recommended meal bolus based on the
    next recommended carbohydrate-to-insulin ratio and the number of
    carbohydrates consumed by the patient during the selected time
    interval; and (6) transmit the recommended meal bolus to an
    administration device configured to automatically dial in and
    administer the number of units of insulin for the recommended meal
    bolus and/or transmit the recommended meal bolus to a portable device
    configured to display the next recommended meal bolus.
  • A glycemic control system comprising data processing hardware in
    communication with memory hardware, a blood glucose meter that
    measures a patient's blood glucose, a user device that receives data
    from the blood glucose meter and displays a user interface on a
    screen, and a computing device associated with an authorized medical
    professional, the data processing hardware configured to: (1) receive
    a current blood glucose measurement for a patient, the time period of
    such measurement and, possibly, a patient input to the user device
    indicating a number of carbohydrates consumed; (2) determine whether
    the time period is pre-meal and whether the meal type is breakfast,
    lunch, dinner or snack; and if it is breakfast: (3) obtain a previous
    basal dose of insulin administered by the patient, a previous
    mid-sleep blood glucose measurement of the patient and a previous
    breakfast blood glucose measurement; (4) determine an adjustment
    factor based on one of the previous mid-sleep blood glucose
    measurements or the previous breakfast blood glucose measurement; (5)
    multiply the previous basal insulin dose times the adjustment factor
    to determine a new basal insulin dose; (6) transmit the new basal
    insulin dose to the user device, causing the user interface to display
    the new basal insulin dose, potentially during the time period of the
    current blood glucose measurement; and thereafter, (7) receive a
    patient input to the user device indicating a number of units of
    insulin administered with the new basal insulin dose and with any
    recommended meal bolus. Additionally, the data processing hardware is
    configured to: (8) obtain a medical professional input to the memory
    hardware indicating a hypoglycemia blood glucose limit for the
    patient; (9) determine whether the current blood glucose measurement
    is less than the hypoglycemia blood glucose limit; and if yes, (10)
    transmit an out-of-range blood glucose alert from the data processing
    hardware to the medical professional computing device; and (11)
    receive hypoglycemia patient instructions from the medical
    professional computing device and transmit them to the user device,
    causing the user interface to display the instructions. Furthermore,
    the data processing hardware is configured to: (12) obtain a medical
    professional input to the memory hardware indicating an insulin
    sensitivity factor and target blood glucose range for the patient;
    (13) determine whether the current blood glucose measurement exceeds
    the midpoint of the target blood glucose range; and if yes, (14)
    determine a correction insulin dose based on a function of the current
    blood glucose measurement, the mid-point of the target blood glucose
    range and the insulin sensitivity factor; and (15) transmit the
    correction insulin dose to the user device, causing the user interface
    to display the correction dose.

"Our mission is to help fix the insulin management problem plaguing
payors, providers and most importantly, the tens of millions of people
with diabetes. It's the biggest opportunity to impact outcomes in
diabetes care right now," says Glytec's Senior Vice President of R&D, Robby
Booth
. "These latest patents are further testimony to our unmatched
record of innovation and leadership in addressing the risks and
complications of insulin therapy that result in overwhelming personal
and societal costs."

About Glytec

Glytec is the pioneer of personalized digital therapeutics, enabling
best practices for inpatient and outpatient insulin management. The
company's patented and FDA-cleared software-as-a-medical-device solutions
improve the safety and health of people with diabetes and make insulin a
more effective medication option for the millions unable to achieve
their treatment goals. Glytec combines evidence-based decision support
technologies with expert clinical services to optimize insulin therapies
in the hospital and at home, leading to reductions in hypoglycemia and
other complications as well as avoidable ED visits, hospitalizations,
readmissions and drug waste. For more information visit www.glytecsystems.com.

View Comments and Join the Discussion!